{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:45Z","timestamp":1793394885697,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,16]]},"DOI":"10.7759\/cureus.71639","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:21:48Z","timestamp":1729099308000},"source":"Crossref","is-referenced-by-count":1,"title":["Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Fahad","family":"Lakhdhir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agha Syed","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Nasir","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Joher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaria","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know","volume":"24 Suppl 2","author":"Muthiah MD","year":"2022","unstructured":"Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know. Diabetes Obes Metab. 2022, 24 Suppl 2:3-14. 10.1111\/dom.14521","journal-title":"Diabetes Obes Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2019.09.007","article-title":"Burden of disease due to nonalcoholic fatty liver disease","volume":"49","author":"Muthiah MD","year":"2020","unstructured":"Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin North Am. 2020, 49:1-23. 10.1016\/j.gtc.2019.09.007","journal-title":"Gastroenterol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba R","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021, 184:2537-64. 10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang DQ","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021, 18:223-38. 10.1038\/s41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2020.12.009","article-title":"Predicting HCC response to multikinase inhibitors with in vivo cirrhotic mouse model for personalized therapy","volume":"11","author":"Huang DQ","year":"2021","unstructured":"Huang DQ, Muthiah MD, Zhou L, et al.. Predicting HCC response to multikinase inhibitors with in vivo cirrhotic mouse model for personalized therapy. Cell Mol Gastroenterol Hepatol. 2021, 11:1313-25. 10.1016\/j.jcmgh.2020.12.009","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan DJ","year":"2022","unstructured":"Tan DJ, Ng CH, Lin SY, et al.. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022, 23:521-30. 10.1016\/S1470-2045(22)00078-X","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt M","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015, 61:1547-54. 10.1002\/hep.27368","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes JG","year":"2019","unstructured":"Abraldes JG, Trebicka J, Chalasani N, et al.. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension. Hepatology. 2019, 69:1287-99. 10.1002\/hep.30314","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.07.036","article-title":"Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis","volume":"44","author":"Nagula S","year":"2006","unstructured":"Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006, 44:111-7. 10.1016\/j.jhep.2005.07.036","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.045","article-title":"Reply to: correspondence regarding \"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement\": Bringing evidence to the NAFLD-MAFLD debate","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, George J. Reply to: correspondence regarding \"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement\": Bringing evidence to the NAFLD-MAFLD debate. J Hepatol. 2020, 73:1575. 10.1016\/j.jhep.2020.07.045","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","author":"Younossi ZM","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024, 10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1078149","article-title":"Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis","volume":"14","author":"Liao Y","year":"2023","unstructured":"Liao Y, Wang L, Liu F, et al.. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. Front Endocrinol (Lausanne). 2023, 14:1078149. 10.3389\/fendo.2023.1078149","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i1.126","article-title":"Management of metabolic-associated fatty liver disease: The diabetology perspective","volume":"29","author":"Jeeyavudeen MS","year":"2023","unstructured":"Jeeyavudeen MS, Khan SK, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol. 2023, 29:126-43. 10.3748\/wjg.v29.i1.126","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196216","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge W","year":"2023","unstructured":"Eskridge W, Cryer DR, Schattenberg JM, et al.. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023, 12:10.3390\/jcm12196216","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan WK","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023, 32:197-213. 10.7570\/jomes23052","journal-title":"J Obes Metab Syndr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i3.549","article-title":"Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact","volume":"29","author":"Tang SY","year":"2023","unstructured":"Tang SY, Tan JS, Pang XZ, Lee GH. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. World J Gastroenterol. 2023, 29:549-60. 10.3748\/wjg.v29.i3.549","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101535","article-title":"The myth of the stigma of fatty liver: What does the evidence show?","volume":"29","author":"Ram\u00edrez-Mej\u00eda MM","year":"2024","unstructured":"Ram\u00edrez-Mej\u00eda MM, Qi X, Abenavoli L, M\u00e9ndez-S\u00e1nchez N. The myth of the stigma of fatty liver: What does the evidence show?. Ann Hepatol. 2024, 29:101535. 10.1016\/j.aohep.2024.101535","journal-title":"Ann Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10662-w","article-title":"Metabolic dysfunction associated fatty liver disease in healthy weight individuals","volume":"18","author":"M\u00e9ndez-S\u00e1nchez N","year":"2024","unstructured":"M\u00e9ndez-S\u00e1nchez N, Brouwer WP, Lammert F, Yilmaz Y. Metabolic dysfunction associated fatty liver disease in healthy weight individuals. Hepatol Int. 2024, 18:884-96. 10.1007\/s12072-024-10662-w","journal-title":"Hepatol Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024, 17.374-444. 10.1159\/000539371","journal-title":"Obes Facts"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00167-021-06631-7","article-title":"Author guidelines for conducting systematic reviews and meta-analyses","volume":"29","author":"Prill R","year":"2021","unstructured":"Prill R, Karlsson J, Ayeni OR, Becker R. Author guidelines for conducting systematic reviews and meta-analyses. Knee Surg Sports Traumatol Arthrosc. 2021, 29:2739-44. 10.1007\/s00167-021-06631-7","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn Z","year":"2014","unstructured":"Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014, 3:123-8. 10.15171\/ijhpm.2014.71","journal-title":"Int J Health Policy Manag"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmw037","article-title":"Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies","volume":"23","author":"Zhong GC","year":"2016","unstructured":"Zhong GC, Liu Y, Chen N, et al.. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies. Hum Reprod Update. 2016, 23:126-38. 10.1093\/humupd\/dmw037","journal-title":"Hum Reprod Update"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams LA","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005, 129:113-21. 10.1053\/j.gastro.2005.04.014","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen AM","year":"2018","unstructured":"Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018, 67:1726-36. 10.1002\/hep.29546","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.11.026","article-title":"Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men","volume":"16","author":"Hwang YC","year":"2018","unstructured":"Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol Hepatol. 2018, 16:1131-1137.e5. 10.1016\/j.cgh.2017.11.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on In-Hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction","volume":"120","author":"Keskin M","year":"2017","unstructured":"Keskin M, Hay\u0131ro\u011flu M\u0130, Uzun AO, G\u00fcven\u00e7 TS, \u015eahin S, Kozan \u00d6. Effect of nonalcoholic fatty liver disease on In-Hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017, 120:1720-6. 10.1016\/j.amjcard.2017.07.107","journal-title":"Am J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg CB","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50:1088-101. 10.2307\/2533446","journal-title":"Biometrics"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2024024","article-title":"Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort","volume":"46","author":"Cheng WC","year":"2024","unstructured":"Cheng WC, Chen HF, Cheng HC, Li CY. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort. Epidemiol Health. 2024, 46:e2024024. 10.4178\/epih.e2024024","journal-title":"Epidemiol Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34637","article-title":"Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients","volume":"153","author":"Kim MN","year":"2023","unstructured":"Kim MN, Han K, Yoo J, Hwang SG, Zhang X, Ahn SH. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023, 153:1448-58. 10.1002\/ijc.34637","journal-title":"Int J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03366-3","article-title":"Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study","volume":"22","author":"May\u00e9n AL","year":"2024","unstructured":"May\u00e9n AL, Sabra M, Aglago EK, et al.. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study. BMC Med. 2024, 22:221. 10.1186\/s12916-024-03366-3","journal-title":"BMC Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.01.029","article-title":"Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study","volume":"110","author":"Xie ZQ","year":"2023","unstructured":"Xie ZQ, Li HX, Wang BK, et al.. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study. Eur J Intern Med. 2023, 110:62-70. 10.1016\/j.ejim.2023.01.029","journal-title":"Eur J Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18011","article-title":"Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States","volume":"60","author":"Kim D","year":"2024","unstructured":"Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024, 60:33-42. 10.1111\/apt.18011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab644","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study","volume":"107","author":"Wang X","year":"2022","unstructured":"Wang X, Wu S, Yuan X, et al.. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022, 107:e745-55. 10.1210\/clinem\/dgab644","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32642","article-title":"Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality","volume":"77","author":"van Kleef LA","year":"2023","unstructured":"van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology. 2023, 77:942-8. 10.1002\/hep.32642","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim D","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. Journal of hepatology. 2021, 75:1284-1291. 10.1016\/j.jhep.2021.07.035","journal-title":"Journal of hepatology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng CH","year":"2023","unstructured":"Ng CH, Lim WH, Hui Lim GE, et al.. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023, 21:931-939.e5. 10.1016\/j.cgh.2022.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis H","year":"2020","unstructured":"Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020, 17:e1003100. 10.1371\/journal.pmed.1003100","journal-title":"PLoS Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030558","article-title":"Impact of sex and gender on clinical management of patients with advanced chronic liver disease and type 2 diabetes","volume":"13","author":"Licata A","year":"2023","unstructured":"Licata A, Russo GT, Giandalia A, Cammilleri M, Asero C, Cacciola I. Impact of sex and gender on clinical management of patients with advanced chronic liver disease and type 2 diabetes. J Pers Med. 2023, 13:10.3390\/jpm13030558","journal-title":"J Pers Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111629","article-title":"Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases","volume":"22","author":"Guti\u00e9rrez-Cuevas J","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021, 22:10.3390\/ijms222111629","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment","volume":"47","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab. 2021, 47:101215. 10.1016\/j.diabet.2020.101215","journal-title":"Diabetes Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154893","article-title":"The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study","volume":"128","author":"Kouvari M","year":"2022","unstructured":"Kouvari M, Chrysohoou C, Skoumas J, Pitsavos C, Panagiotakos DB, Mantzoros CS. The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study. Metabolism. 2022, 128:154893. 10.1016\/j.metabol.2021.154893","journal-title":"Metabolism"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i11.1584","article-title":"Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity","volume":"13","author":"Pal P","year":"2021","unstructured":"Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol. 2021, 13:1584-610. 10.4254\/wjh.v13.i11.1584","journal-title":"World J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/302307-assessing-mortality-disparities-among-non-alcoholic-fatty-liver-disease-metabolic-dysfunction-fatty-liver-disease-and-metabolic-dysfunction-associated-liver-disease-a-comprehensive-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:21:49Z","timestamp":1729099309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/302307-assessing-mortality-disparities-among-non-alcoholic-fatty-liver-disease-metabolic-dysfunction-fatty-liver-disease-and-metabolic-dysfunction-associated-liver-disease-a-comprehensive-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.71639","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}